Ardea Biosciences, Inc.  

(Public, NASDAQ:RDEA)   Watch this stock  
Find more results for RDEA
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 1.18B
P/E     -
Div/yield     -
EPS -3.91
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin -2772.49% -1185.23%
Operating margin -2778.66% -1186.30%
EBITD margin - -1176.15%
Return on average assets -99.42% -84.60%
Return on average equity -115.30% -108.65%
Employees 107 -
CDP Score - -

Address

4939 Directors Place
San Diego, CA 92121
United States - Map
+1-858-6526500 (Phone)
+1-858-6250760 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ardea Biosciences, Inc. (Ardea) is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The Company´┐Żs product portfolio includes Lesinurad (RDEA594), RDEA3170 and BAY 86-9766 (RDEA119). Lesinurad (RDEA594) is an inhibitor of the URAT1 kidney transporter for the treatment of gout. RDEA3170 is a URAT1 kidney transporter inhibitors for the treatment of gout. BAY 86-9766 (RDEA119) is a MEK inhibitor for the treatment of cancer. On June 19, 2012, AstraZeneca PLC acquired the Company.